In this study, we evaluate whether there is preclinical rationale to target glutaminolysis as a treatment for chondrosarcoma by determining the expression levels of glutaminase in chondrosarcoma primary tumours and by evaluating the effect of metformin, phenformin, chloroquine and CB-839 on chondrosarcoma cells. This evidence concerns the gene GLS and chondrosarcoma.